Vir Biotechnology Inc VIR

$11.17 -0.12 (-1.06%)

Valuation

Market cap
1,890,143,000
Revenue TTM
$68,560,000
Net income TTM
$-437,990,000
PE ratio
0.00
Forward PE
—
Profit margin
-638.84%
Debt to equity
0.00

Trading

Volume
2,180,600
Avg volume
1,893,302
Day's range
$10.95 – $11.73
Shares out
169,216,000
Stochastic %K
60%
Beta
1.59
Analysts
Strong Sell
Price target
$20.78

Price

Company profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A a...

Show more

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 906 4324
Website
https://www.vir.bio
Address
1800 Owens Street, Suite 900, San Francisco, United States

Latest news

Stocktwits

Doozio Oct 3, 11:35 PM
$VIR out of the tightness as long as no faaatch 💣 lands ………
0 replies
Aksunbay Oct 3, 9:21 AM
$VIR When will there be any news here?
0 replies
PCIntern Oct 1, 8:09 PM
$VIR boy, they really dicked around with this stock’s SP today. It was positively artistic.
3 replies
Dunnieboy1 Oct 1, 5:45 PM
$VIR In a report released yesterday, Roanna Ruiz from Leerink Partners reiterated a Buy rating on Vir Biotechnology, with a price target of $17.00. The company’s shares closed last Tuesday at $10.65
0 replies
Thinkingman91 Oct 1, 3:54 PM
$VIR we aren’t celebrating early
0 replies
Mhand Oct 1, 12:45 PM
$VIR https://investors.vir.bio/news/news-details/2026/Vir-Biotechnology-Appoints-Aziz-Sawaf-as-Chief-Financial-Officer/default.aspx
0 replies
metalcook Sep 30, 4:45 PM
$VIR my opinion Good Hepd data will breng us nowhere Stellar Hepd data (better than phase2b)=14-15$ Vir5818 good data = to the moon Failure VIR5818 and good Hepd data = 8-11$ range.
1 replies
PCIntern Sep 30, 3:31 PM
$VIR very nice action…could this be “it”?? Nah. Somehow I doubt it.
1 replies